Advanced Pancreatic Cancer
Oncology·MeSH: Pancreatic Neoplasms
Prevalence
8.0 / 100K
Incidence
13.1 / 100K/yr
7 drugs in development·6 companies·3 clinical trials
Drug Pipeline by Phase
Phase 3(2)
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| AB680 | Arcus Biosciences, Inc. (RCUS) |
Phase 1/Phase 2(1)
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| sil204 | Silexion Therapeutics Corp (SLXN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced Pancreatic Cancer?
BioSniper tracks 7 drugs in development for Advanced Pancreatic Cancer across 6 companies.
How many clinical trials target Advanced Pancreatic Cancer?
There are 3 clinical trials targeting Advanced Pancreatic Cancer tracked by BioSniper.
What is the prevalence of Advanced Pancreatic Cancer?
The estimated prevalence of Advanced Pancreatic Cancer is approximately 8.0 per 100,000 population.
Deep-dive into Advanced Pancreatic Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis